ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      59,979.20
      1.26%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aeterna Zentaris Inc (AEZS)

      7. Aeterna Zentaris Inc (AEZS) News

      AEZS

      Aeterna Zentaris (AEZS)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AEZS
      DateTimeSourceHeadlineSymbolCompany
      04/16/20109:04AMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      04/15/20108:40PMPR Newswire (US)Æterna Zentaris to Raise US$15 Million in Registered Direct OfferingNASDAQ:AEZSAeterna Zentaris Inc
      04/15/20107:30AMPR Newswire (US)Æterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Program with Perifosine iNASDAQ:AEZSAeterna Zentaris Inc
      04/13/20107:30AMPR Newswire (US)Æterna Zentaris to Present Data on Erk/PI3K Inhibitors at Upcoming AACR Annual MeetingNASDAQ:AEZSAeterna Zentaris Inc
      04/08/20108:35AMPR Newswire (US)Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal CancerNASDAQ:AEZSAeterna Zentaris Inc
      04/06/20109:15AMGlobeNewswire Inc.Skymark Research Initiates Independent Research Coverage on AEterna Zentaris Inc.NASDAQ:AEZSAeterna Zentaris Inc
      04/05/201011:06AMDow Jones NewsFDA Fast Tracks Keryx Colorectal Cancer Drug, Shares SoarNASDAQ:AEZSAeterna Zentaris Inc
      04/05/20108:40AMPR Newswire (US)Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for the Treatment of Refractory Advanced Colorectal CanNASDAQ:AEZSAeterna Zentaris Inc
      04/05/20108:30AMPR Newswire (US)Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal CancerNASDAQ:AEZSAeterna Zentaris Inc
      03/31/20105:30PMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      03/31/20107:30AMPR Newswire (US)Æterna Zentaris to Present at BioFinance in Toronto on April 7NASDAQ:AEZSAeterna Zentaris Inc
      03/30/20105:31PMEdgar (US Regulatory)Annual and Transition Report (foreign private issuer) (20-F)NASDAQ:AEZSAeterna Zentaris Inc
      03/30/201011:55AMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      03/25/20104:57PMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      03/25/20104:55PMEdgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:AEZSAeterna Zentaris Inc
      03/25/20106:50AMGlobeNewswire Inc.Biotech Stock Alert for AEterna Zentaris Inc. Issued by BeaconEquityNASDAQ:AEZSAeterna Zentaris Inc
      03/24/20107:00AMPR Newswire (US)Æterna Zentaris Reports Fourth Quarter and Full-Year 2009 Financial and Operating ResultsNASDAQ:AEZSAeterna Zentaris Inc
      03/17/20107:30AMPR Newswire (US)Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010NASDAQ:AEZSAeterna Zentaris Inc
      03/12/20105:15PMEdgar (US Regulatory)Securities Registration (foreign private issuer) (F-3/A)NASDAQ:AEZSAeterna Zentaris Inc
      02/23/20105:23PMEdgar (US Regulatory)Securities Registration (foreign private issuer) (F-3)NASDAQ:AEZSAeterna Zentaris Inc
      02/23/20108:00AMPR Newswire (US)AEterna Zentaris CEO to Take Part in Panel Discussion on Cancer Therapy at Upcoming RBC Capital Markets Healthcare Conference inNASDAQ:AEZSAeterna Zentaris Inc
      02/11/201010:32AMEdgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:AEZSAeterna Zentaris Inc
      02/03/20108:35AMPR Newswire (US)AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-040NASDAQ:AEZS
      01/29/20108:35AMPR Newswire (US)AEterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of AdvancedNASDAQ:AEZS
      01/29/20108:30AMPR Newswire (US)Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced NASDAQ:AEZS
      01/27/20104:00PMPR Newswire (US)Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in ColorNASDAQ:AEZS
      01/25/20108:35AMPR Newswire (US)AEterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, DouNASDAQ:AEZS
      01/25/20108:30AMPR Newswire (US)Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-ControllNASDAQ:AEZS
      01/22/20104:05PMPR Newswire (US)AEterna Zentaris Receives NASDAQ Notification Related to Minimum Bid PriceNASDAQ:AEZS
      01/21/20108:35AMPR Newswire (US)AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) atNASDAQ:AEZS
       Showing the most relevant articles for your search:NASDAQ:AEZS